Alzheimer's disease (AD) is a neurodegenerative disorder associated with amyloid accumulation and autophagic changes. Parkin is an E3 ubiquitin ligase involved in proteasomal and autophagic clearance. We previously demonstrated decreased parkin solubility and interaction with the key autophagy enzyme beclin-1 in AD, but tyrosine kinase inhibition restored parkin-beclin-1 interaction. In the current studies, we determined the mechanisms of nilotinibinduced parkin-beclin-1 interaction, which leads to amyloid clearance. Nilotinib increased endogenous parkin levels and ubiquitination, which may enhance parkin recycling via the proteasome, leading to increased activity and interaction with beclin-1. Parkin solubility was decreased and autophagy was altered in amyloid expressing mice, suggesting that amyloid stress affects parkin stability, leading to failure of protein clearance via the lysosome. Isolation of autophagic vacuoles revealed amyloid and parkin accumulation in autophagic compartments but nilotinib decreased insoluble parkin levels and facilitated amyloid deposition into lysosomes in wild type, but not parkin −/− mice, further underscoring an essential role for endogenous parkin in amyloid clearance. These results suggest that nilotinib boosts the autophagic machinery, leading to increased level of endogenous parkin that undergoes ubiquitination and interacts with beclin-1 to facilitate amyloid clearance. These data suggest that nilotinib-mediated autophagic changes may trigger parkin response via increased protein levels, providing a therapeutic strategy to reduce Aβ and Tau in AD. 
Introduction
Alzheimer's disease (AD) is an aging disorder characterized by deposition of β-amyloid (Aβ plaques and hyper-phosphorylated Tau (p-Tau)). Amyloid precursor protein (APP) is sequentially cleaved by secretases to yield C-terminal APP fragments (CTFs) and amyloid peptides Aβ and Aβ [1] [2] [3] [4] giving rise to extracellular plaques. The tyrosine kinase Abelson (Abl) is distributed in the nucleus and cytoplasm and involved in a wide range of functions, including apoptosis [5] . Abl phosphorylation at tyrosine 412 (T412) is elevated in the hippocampus and entorhinal cortex in AD brains [6, 7] , and Abl phosphorylates Tau at several tyrosine residues [6, 8] . In primary neuronal culture, Abl inhibition prevents Aβ fibrils and cell death [9] , and hippocampal injection of Aβ fibrils results in upregulation of Abl levels [10] . Furthermore, Abl is also increased in Parkinson's Disease (PD) brains, while Abl inhibition leads to autophagic α-synuclein degradation in PD models [11] .
It was previously reported that Abl inhibition may activate parkin and improve dopaminergic neuron survival in PD models [12] . Decreased parkin solubility is associated with defects in autophagic clearance of β-amyloid and p-Tau in postmortem AD brains [13] , indicating that aging may alter parkin function. Parkin mediates mitophagy [14] [15] [16] [17] , and clears autophagic vacuoles (AVs) in AD mice [13, 18] . These data led to the hypothesis that tyrosine kinase inhibition (TKI) will activate parkin and facilitate autophagic clearance of β-amyloid and p-Tau. Nilotinib is a second-generation TKI, which was approved by the US Food and Drug Administration (FDA) in 2007 for the treatment of adult chronic myelogenous leukemia (CML) [19] [20] [21] . We previously demonstrated that nilotinib increases parkin-beclin-1 interaction, leading to clearance of β-amyloid and p-Tau in AD models [22] . The current studies further examined the effects of nilotinib on endogenous parkin function to mediate autophagic clearance. Here, we report that TKI via nilotinib increases endogenous parkin levels and self-ubiquitination, which may enhance physiological recycling via the proteasome, leading to increased activity and interaction with beclin-1. Together, these data suggest that decreased parkin solubility in AD and sporadic PD [13, 23] may be due to inefficient ubiquitination, leading to parkin instability and decreased parkin-beclin-1 interaction. Nilotinib alters autophagy, triggering an increase in parkin level, perhaps enhancing parkin recycling. The current studies provide novel mechanistic evidence that the FDA-approved drug, nilotinib, can increase endogenous parkin level and function in response to autophagic changes to clear amyloid, suggesting therapeutic benefits for AD.
Materials and methods
Human postmortem brain tissues Human postmortem samples were obtained from John's Hopkins University brain bank. Patients' description and sample preparation are summarized in [13] . Data were analyzed as mean±SEM, using two-tailed t test (P <0.05).
Stereotaxic injection Lentiviral constructs encoding LacZ, or Aβ [24] were stereotaxically injected 1×10 6 multiplicity of infection (m.o.i) bilaterally into the CA1 hippocampus of 1-year-old male C57BL/6 or parkin −/− . All procedures were approved by the Georgetown University Animal Care and Use Committee (GUACUC). Nilotinib was dissolved in DMSO and a total volume of 30 μl was IP-injected once a day for 3 weeks. Half the animals received DMSO and the other half received nilotinib in DMSO.
Western blot Brain tissues were homogenized in 1× STEN buffer [13] , centrifuged at 10,000×g for 20 min at 4°C, and the supernatants containing the soluble fraction were collected. To extract the insoluble fraction, pellets were resuspended in either 4 M urea or 30 % formic acid and centrifuged at 10,000×g for 20 min at 4°C. Parkin was probed (1:1,000) with PRK8 antibody as indicated [25] . Rabbit polyclonal antibodies anti-beclin-1 (1:1,000). Total Abl was probed with (1:500) rabbit polyclonal (K12) antibody (Thermo Fisher), or p-Abl (T412) with (1:500) rabbit polyclonal antibody (Millipore). Phosphotyrosine proteins were probed (1:1,000) with rabbit polyclonal antibody (Cell signaling). β-actin was probed (1:1,000) with polyclonal antibody (Cell Signaling Technology, Beverly, MA, USA). Rabbit polyclonal (1:1,000) tubulin (Thermo Scientific) was used. MAP-2 was probed (1:1,000) with mouse monoclonal antibody (Pierce).
Immunohistochemistry was performed on 20-μm-thick 4 % paraformaldehyde (PFA)-fixed cortical brain sections. Aβ was probed (1:200) with rabbit polyclonal specific anti-Aβ antibody (Zymed) that recognizes a.a.1-42, and (1:200) mouse monoclonal antibody (4G8) that recognizes a.a. 17-24 (Covance) and counterstained with DAPI. Parkin was immunoprobed (1:200) with mouse anti-parkin (PRK8) antibody that recognizes a.a. 399-465 (Signet Labs, Dedham, MA) and rabbit polyclonal (1:200) anti-parkin (AB5112) antibody that recognizes a.a. 305-622 (Millipore) and counterstained with DAPI. Mouse monoclonal (6E10) antibody (1:100) with DAB were used (Covance) and thioflavin-S was performed according to manufacturer's instructions (Sigma). Stereological methods were applied by a blinded investigator using unbiased stereology analysis (Stereologer, Systems Planning and Analysis, Chester, MD) as described in [13, 24] .
Aβ and p-Tau enzyme-linked immunosorbent assay (ELISA) using specific p-Tau, Aβ and Aβ ELISA and caspase-3 activity were performed according to manufacturer's protocol as described in [13, 24] . Subcellular fractionation to isolate autophagic vacuoles Animal brains were homogenized at low speed (Cole-Palmer homogenizer, LabGen 7, 115 Vac) in 1× STEN buffer and centrifuged at 1,000×g for 10 min to isolate the supernatant from the pellet. The pellet was resuspended in 1xSTEN buffer and centrifuged once to increase the recovery of lysosomes. The pooled supernatants were then centrifuged at 100,000 rpm for 1 h at 4°C to extract the pellet containing autophagic vacuoles (AVs) and lysosomes. The pellet was then resuspended in 10 ml (0.33 g/ml) 50 % metrizamide and 10 ml in cellulose nitrate tubes. A discontinuous metrizamide gradient was constructed in layers from bottom to top as follows: 6 ml of pellet suspension, 10 ml of 26 %; 5 ml of 24 %; 5 ml of 20 %; and 5 ml of 10 % metrizamide.
After centrifugation at 100,000 rpm for 1 h at 4°C, the fraction floating on the 10 % layer (lysosome) and the fractions banding at the 24 %/20 % (AV 20) and the 20 %/10 % (AV10) interphases were collected by a syringe and examined.
Ubiquitination assay Parkin or ubiquitin were separately immunoprecipitated in 100 μl (100 μg of proteins) 1× STEN buffer using (1:100) anti-ubiquitin monoclonal antibody (Abnova) or (1:100) anti-parkin mouse monoclonal antibody (PRK8; Signet Labs; Dedham, MA), respectively. Following immunoprecipitation and normalization of the aliquots, 300 ng of each substrate protein (parkin and ubiquitin) were mixed in the presence of 1 μg recombinant human ubiquitin (Boston Biochem, MA), 100 mm ATP, 1 μg recombinant UbcH7 (Boston Biochem), 40 ng E1 recombinant enzyme (Boston Biochem) and incubated at 37°C in an incubator for 20 min. The reaction was heat inactivated by boiling for 5 min and the substrates were analyzed by WB.
Transmission electron microscopy Brain tissue were fixed in (1:4, v:v) 4 % paraformaldehyde-picric acid solution and 25 % glutaraldehyde overnight, then washed three times in 0.1 M cacodylate buffer and osmicated in 1 % osmium tetroxide/ 1.5 % potassium ferrocyanide for 3 h, followed by another three times wash in distilled water. Samples were treated with 1 % uranyl acetate in maleate buffer for 1 h, washed three times in maleate buffer (pH 5.2), then exposed to a graded cold ethanol series up to 100 % and ending with a propylene oxide treatment. Samples are embedded in pure plastic and incubated at 60°C for 1-2 days. Blocks are sectioned on a Leica ultracut microtome at 95 nm, picked up onto 100 nm formvar-coated copper grids, and analyzed using a Philips Technai Spirit transmission EM. All images were collected by a blind investigator.
Cell culture and transfection Rat neuroblastoma B35 cells were grown in 24 well dishes (Falcon) as previously described [13, 24] . Transient transfection was performed with 3 μg Aβ 1-42 cDNA, or 3 μg LacZ cDNA for 24 h. Cells were treated with 10 μM nilotinib (AMN-107, Selleck Chemical, LLC, USA) for 24 h and harvested 48 h after transfection.
Parkin ELISA was performed on brain soluble brain lysates (in STEN buffer) or insoluble brain lysates (4 M urea) using parkin kit (MYBioSource) in 50 μl (1 μg/μl) of brain lysates detected with 50 μl primary antibody (3 h) and 100 μl anti-rabbit antibody (30 min) at RT. Extracts were incubated with stabilized chromogen for 30 min at RT and solution was stopped and read at 450 nm, according to manufacturer's protocol.
Parkin E3 ubiquitin ligase activity An E3LITE Customizable Ubiquitin Ligase Kit (Life Sensors, UC#101), which measures the mechanisms of E1-E2-E3 activity in the presence of different ubiquitin chains was used. UbcH7 was used as an E2 that provides maximum activity with parkin E3 ligase and added E1 and E2 in the presence of recombinant ubiquitin, including WT or no lysine mutant (K0) to determine the lysine-linked type of ubiquitin. E3 was added as IP parkin (normalized to make sure equal amount of protein loaded) to an ELISA microplate that captures poly-ubiquitin chains formed in the E3-dependent reaction, which was initiated with ATP at RT for 60 min. Controls included, E1-E2-E3, no parkin as an E3 or only IgG were used and poly-ubiquitin chain read in addition to E1, E2, and Aβ 1-42 without parkin and assay buffer. Plates were washed three times and incubated with streptavidin-HRP for 5 min and read on a chemiluminescense plate reader.
20S proteasome activity assay Brain extracts (100 μg) were incubated with 250 μM of the fluorescent 20S proteasome specific substrate Succinyl-LLVY-AMC at 37°C for 2 h. The medium was discarded and proteasome activity was measured in tissue homogenates as previously described [13, 24] .
Results

Nilotinib increases parkin level and ubiquitination
We previously demonstrated decreased parkin-beclin-1 interaction in AD brains [22] , which display decreased parkin solubility and autophagic changes [13] . TKI reversed the loss of parkin-beclin-1 interaction and led to increased autophagic clearance of Aβ and p-Tau [13, 22] . To determine how TKI alters endogenous parkin response to interact with Beclin-1, 2-months old wild type C57BL/6 mice were treated with intraperotineal (I.P.) injection of 10 mg/kg nilotinib or DMSO for 3 weeks [22] . Western blot analysis of total brain lysates showed an increase (80 %) in parkin levels (Fig. 1a, b , p <0.05, n =9) and significant LC3-II accumulation relative to LC3-I (67 %) and actin (52 %) in nilotinib-treated mice (Fig. 1a, b ) compared to DMSO, suggesting autophagic alteration via autophagosome formation. A significant increase (54 %) in beclin-1 was also observed (Fig. 1a, b) , further suggesting autophagic changes in nilotinib-treated mice. To determine parkin modification in response to nilotinib, rat B35 neuroblastoma cells were treated with 10 μM nilotinib or DMSO (1 μl) for 24 h and in vitro ubiquitination assays were performed to determine whether parkin was ubiquitinated, which may affect its recycling and prevent its accumulation as observed in AD [13] and PD [23] brains. Parkin (E3) was immunoprecipitated from transfected B35 cells, which had increased parkin levels upon nilotinib treatment, but the parkin IPs were normalized after protein assays (Fig. 1c, inset ) to ensure equal amounts of parkin are used in the ELISA. An enzymatic mix of E1, E2 (UbcH7), and ATP were added with either WT ubiquitin containing all seven lysines or no lysine (K0) ubiquitin [26] to parkin, and IgG and no parkin were used as controls. Nilotinib increased parkin auto- ubiquitination compared to DMSO or K0 control (Fig. 1c , 170 %, n =5, p <0.05). A control E1-E2-E3 mix and polyubiquitin chains were also used to control for chemiluminescence reading. We previously demonstrated using the same ubiquitination assays that parkin can self-ubiquitinate via K48 and K63 ubiquitin linkages [26] . To ascertain that nilotinib promotes parkin ubiquitination, another in vitro assay was performed as we previously described [25, 26] . Parkin was immunoprecipitated from B35 cells treated with DMSO or nilotinib (42 h) and 20 μM proteasome inhibitor MG132 for 6 h, and recombinant E1, E2 (UbcH7), ubiquitin and ATP were added at 60°C for 1 h. Immunoprecipitation of ubiquitin showed higher levels of ubiquitinated parkin in nilotinibtreated cells compared to DMSO with WT but not K0 ubiquitin (Fig. 1d, n =5) , suggesting that nilotinib increases parkin ubiquitination. Additionally, to ascertain that nilotinib increased parkin ubiquitination, parkin was immunoprecipitated and showed a higher smear with ubiquitin antibodies (Fig. 1e , n =5), suggesting that nilotinib increased the level of parkin ubiquitination. These results suggest that ubiquitinated parkin may increase recognition by the proteasome for degradation.
To determine whether parkin levels are also increased in response to amyloid stress, rat B35 neuroblastoma cells were transfected with 3 μg human Aβ 1-42 cDNA (or LacZ) for 24 h, and treated with 10 μM for an additional 24 h. Parkin levels were measured via ELISA using parkin −/− brain extracts as a specificity control (Fig. 1f ). An increase (39 %) in parkin level was observed with Aβ 1-42 +nilotinib (47 %) compared to Aβ 1-42 + DMSO or control (Fig. 1f , n =12, p <0.05), suggesting that nilotinib increases parkin levels in response to Aβ 1-42 stress, which alone did not alter parkin level. To further determine whether alteration of parkin levels is associated with proteasome function, the chymotrypsin-like assay was used with the 20S proteasome inhibitor lactacystin as a specificity control (Fig. 1g) . Proteasome activity was decreased (43 %, p <0.05, n =12) in Aβ 1-42 cells, and nilotinib reversed these effects compared to LacZ cells (Fig. 1f) .
To determine nilotinib effects on parkin fate in vivo, we stereotaxically injected 1×10 6 m.o.i lentiviral Aβ 1-42 bilaterally into the hippocampus of 1-year-old male C57BL/6 (WT) or parkin −/− mice (generated on a C57BL/6 background) [27] , and 3 weeks later we injected 10 mg/kg nilotinib I.P. once a day for three additional weeks. Autophagic vacuoles (AVs) were isolated [13] and parkin levels were measured by ELISA. Parkin was significantly increased (2.8-fold, Fig. 1h , p <0.05, n =5) in AV10 (10 % gradient) and AV20 (6-fold) in lentiviral Aβ brains compared to control (DMSO). Nilotinib significantly reduced parkin level (1.25-fold) in AV10 and increased it in the lysosomal fraction (5-fold) compared to control, suggesting parkin transfer from AV10 to lysosomes for degradation [28] .
Nilotinib is a non-specific Abl inhibitor that increases parkin level, leading to Aβ clearance To determine whether Abl affects parkin activity via phosphorylation as previously reported [12] , we immunoprecipitated parkin from nilotinibtreated mice or B35 cells, but we did not observe any tyrosine phosphorylation with the pan-phosphotyrosine antibody, suggesting that parkin is not a substrate for phosphorylation by Abl. However, nilotinib decreased the levels of phosphorylated T412 Abl (Fig. 2a, 46 %, p <0.05, n =9), and pan-phosphotyrosine (Fig. 1a , second blot) relative to actin in WT mice, suggesting that nilotinib is not a specific Abl inhibitor. To further examine the effects of TKI on parkin modification, rat neuroblastoma B35 cells were co-transfected with 3 μg human Aβ and Abl cDNAs or Aβ 1-42 cDNA and Abl shRNA (ThermoFisher) for 24 h and the proteasome was inhibited with 20 μM MG132 for 6 h to allow accumulation of ubiquitinated parkin. Parkin levels were significantly decreased when Abl was overexpressed (Fig. 2b, c , n =12, p <0.05), compared to control, but parkin levels significantly increased (58 %) when Abl expression was blocked relative to actin compared to control. Parkin was immunoprecipitated ( Fig. 2b ) and probed with ubiquitin, which showed an increase in ubiquitinated parkin smear when Abl expression was blocked with shRNA ( Fig. 2b, 2nd blot, n =12). Additionally, the 50-kDa band that corresponds to parkin was decreased (41 %, n =12) with Abl overexpression and increased with Abl shRNA (81 %) relative to actin in comparison to control (Fig. 2b , p < 0.05), suggesting that Abl affects parkin ubiquitination and level. Furthermore, to determine whether nilotinib effects are mediated via Abl inhibition, transfected B35 cells were treated with 10 μM nilotinib for 24 h without proteasome inhibition. ELISA showed that Aβ 1-42 expression resulted in significant increases in secreted (195 ng/ml, media), soluble (98 ng/ml, STEN extract) and insoluble (109 ng/ml, 30 % formic acid extract) Aβ 1-42 compared to control (Fig. 2d , p <0.05, n =12), and nilotinib reduced secreted (130 ng/ml), soluble (31 ng/ml), and insoluble (51 ng/ml) Aβ . Overexpression of Abl (Fig. 2b) with Aβ 1-42 led to a non-significant increase in secreted (211 ng/ml), soluble (109 ng/ml), and insoluble (77 ng/ml) Aβ , and nilotinib reversed secreted (140 ng/ml), soluble (21 ng/ml) and insoluble (25 ng/ml) Aβ 1- C57BL/6 mice, 20-μm-thick hippocampal sections were stained with T412 Abl (Fig. 2e) and parkin (Fig. 2f , insert is staining of parkin −/− brains to PRK8 specificity), showing co-localization between parkin and phosphorylated T412 Abl (Fig. 2g) . Nilotinib significantly decreased (62 % by stereology) T412 Abl (Fig. 2h ) and increased parkin (29 % by stereology) levels (Fig. 2i, j, p <0 .05, n =6). Nilotinib also affected parkin expression pattern in mice, showing more parkin in the cell bodies and cellular processes (Fig. 2i, insert) .
Decreased parkin solubility in transgenic AD models and nilotinib increases soluble parkin level, leading to amyloid clearance We previously showed that insoluble parkin levels were increased in postmortem AD brains [13] , so we examined the levels of Abl in these brain lysates (n =12 AD and 7 control, described in [13] ). Significantly increased levels (90 %) of total ( Fig. 3a) and T412 (184 %) Abl were detected in AD brains (Fig. 3a) . The ratio of p-Abl over total Abl (Fig. 3b ) was also increased (102 %). In contrast, soluble parkin was decreased (70 %) in AD cortex (Fig. 3a, b) relative to actin, suggesting that Abl activation and parkin inactivity may be a vulnerability to brain aging. To determine nilotinib effects on parkin function in AD models in vivo, 8-12-month-old male AD transgenic mice (Tg-APP) harboring the Swedish K670N/M671L, Dutch E693Q and Iowa D694N mutations [29] were treated with 10 mg/kg IP injection of nilotinib for 3 weeks. Significant increases in total (51 %) and T412 Abl (64 %) were detected in Tg-APP compared to control (Fig. 3c, p <0 .05, n =11), while nilotinib reversed these increases (Fig. 3e, p <0 .05, n =11). Abl inhibition with nilotinib also reduced the level of CTFs (44 %, p <0.05, n =11) relative to MAP-2, with no effects on secretases as previously shown [22] . No changes in soluble or insoluble parkin were detected in control mice±nilotinib (Fig. 3, n =9 ). However, nilotinib increased the level of soluble parkin from 64 ng/ml in Tg-APP+DMSO to 119 ng/ml (Fig. 3d , n =11, p <0.05) while it decreased insoluble parkin level from 54 ng/ml to 31 ng/ml in nilotinib-treated mice (Fig. 3d, p <0 .05, n =11). Taken together, these data indicate that nilotinib increases soluble parkin level and ubiquitination, suggesting increased activity and proteasomal recycling, leading to prevention of insoluble parkin accumulation. Tg-APP mice expressed significantly higher levels of soluble (156 ng/ml) and insoluble (173 ng/ml) Aβ 1-42 compared to 1-year-old control±nilotinib (Fig. 3e, p <0 .05, n =9) while nilotinib reduced soluble Aβ 1-42 (35 ng/ml, which remained significantly higher than control) and reversed the increase in insoluble Aβ . Significant increases in soluble (281 ng/ml) and insoluble (250 ng/ml) Aβ were also detected in Tg-APP mice compared to 1-year-old control (Fig. 3f,  p <0 .05, n =9), and were reversed by nilotinib. p-Tau was also increased at ser 396 (109 ng/ml) and AT8 (288 ng/ml) compared to 1-year-old control (Fig. 2g, (Fig. 3i , p <0.05, n =11). These data are consistent with our previous report showing that TKI, either via nilotinib or bosutinib, can increase amyloid clearance [22] .
Nilotinib promotes autophagic clearance of amyloid in a parkin-beclin-1-dependent manner WB of total brain lysates in 1-year-old WT mice injected with lentiviral Aβ 1-42 showed a significant decrease in T412 (45 %) relative to total Abl following daily treatment with 10 mg/kg nilotinib for 3 weeks (Fig. 4a, p <0 .05, n =9). An increase in parkin level (62 %) was associated with a similar increase in beclin-1 (53 %) relative to MAP-2 (Fig. 4a, p <0 .05, n =9), consistent with the hypothesis that Abl inhibition may mediate clearance via increased parkin activity. LC3-II and its precursor LC3-I were both increased in lentiviral Aβ 1-42 mice (DMSO) relative to MAP-2, but nilotinib led to LC3-II disappearance and decreased levels of LC3-I relative to MAP-2 (Fig. 4a, 45 %, p <0.05, n =9). Interestingly, parkin −/− mice had higher levels of beclin-1 relative to actin (Fig. 4b , 120 %, n =9) compared to control but nilotinib did not clear LC3-II in parkin −/− mice (Fig. 3b) , suggesting that despite the increase in beclin-1, nilotinib cannot clear autophagosomes in parkin −/− mice. To verify the effects of nilotinib on parkin level and autophagic markers beclin-1 and LC3, Tg-APP mice were treated I.P. with 10 mg/kg nilotinib once a day for 3 weeks. A significant increase in parkin (Fig. 4c, 41 %, p <0.05, n =9), beclin-1 (45 %), and LC3-I (26 %) relative to tubulin were observed in nilotinib-treated mice, which showed disappearance of LC3-II (Fig. 4c) , suggesting autophagic clearance. To ascertain that autophagy is involved in nilotinib-mediated amyloid clearance, beclin-1 expression was blocked with shRNA (ThermoFisher) and autophagy was inhibited with 100 nM bafilomycin for 3 h in rat B35 neuroblastoma cells (Fig. 4d) . Beclin-1 shRNA expression showed that Aβ 1-42 levels were unaffected in the media with nilotinib compared to Aβ expressing cells, and were significantly higher than Aβ 1-42 + nilotinib (Fig. 4d) . Soluble and insoluble Aβ 1-42 were partially (42 and 21 %, respectively) decreased compared to Aβ cells, but remained twofold higher compared to Aβ 1-42 + nilotinib (Fig. 4d, p <0.05, n =12) , indicating that beclin-1 is required for complete Aβ 1-42 clearance. Secreted Aβ (media) may have accumulated in the first 24 h after transfection, prior to nilotinib treatment. Furthermore, inhibition of autophagy with bafilomycin A1, led to Aβ 1-42 accumulation and nilotinib failed to reverse these effects (Fig. 4d, n =12) .
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To further determine whether autophagy mediates clearance of amyloid proteins in vivo, AVs were isolated [13] and amyloid was measured via ELISA. Aβ was detected in AV10 and AV20, but not lysosomes, in lentiviral Aβ 1-42 WT brain (Fig. 4e, n =5) (Fig. 4f , n =5) but nilotinib decreased p-Tau levels in AV10 (4.3-fold, p <0.05, N =5) and increased it in AV20 (1.39-fold) and lysosomes (6.27-fold). Similar levels of p-Tau were detected in AV10 in parkin −/− compared to WT mice but p-Tau was decreased in AV20 compared to WT (2.8-fold), and no p-Tau was detected in lysosomes (Fig. 4f, n =5) . Nilotinib did not decrease p-Tau in AV10 and p-Tau was decreased in AV20 of Aβ 1-42 parkin −/ − (6-fold) compared to Aβ 1-42 WT mice (Fig. 4f, p <0 .05).
Nilotinib increases parkin level and decreases plaque load in Tg-APP mice Staining of 20-μm brain sections shows plaque formation in Tg-APP mice treated with DMSO ( Fig. 5a-c representing different animals), though plaque staining disappeared in the nilotinib group after 3-week treatment ( Fig. 5e-g ). Thioflavin-S staining was also decreased in nilotinib-treated Tg-APP mice (Fig. 5h ) compared to DMSO (Fig. 5d ). Higher magnification shows endogenous parkin (Fig. 5i ) and plaque deposition (Fig. 5i, k) in Tg-APP mice hippocampus. Nilotinib increases endogenous parkin (Fig. 5l) , resulting in plaque disappearance (Fig. 5m, n) . Using different parkin antibodies to show parkin (Fig. 5o) and plaque (Fig. 5p, q) , Nilotinib increased parkin levels (Fig. 5r ) and dissolved plaques (Fig. 5s, t) . To determine whether parkin targets intracellular Aβ [24] to decrease extracellular plaque load, lentiviral injection was used to express intracellular Aβ 1-42 within the hippocampus (Fig. 5u , inset higher magnification) and nilotinib clearance of intracellular Aβ (Fig. 5v , inset is of higher magnification). Lentiviral injection into the hippocampus led to intracellular Aβ 1-42 expression throughout the cortex (Fig. 5w , inset higher magnification) and, again, nilotinib eliminated Aβ 1-42 accumulation (Fig. 5x, inset is of higher magnification) . Lower magnification images show plaques in Aβ 1-42 expressing mice 6 weeks post-injection (Fig. 6a-c) . Nilotinib (daily for 3 weeks) eliminates plaques in Aβ 1-42 WT mice (Fig. 6d-f) . Aβ 1-42 expression in parkin −/− mice showed more plaques (Fig. 6g-i ) and nilotinib did not reduce plaques (Fig. 6j-l) . Transmission electron microscopy revealed (n =6 animals per treatment) autophagic defects in lentiviral Aβ 1-42 expressing mice [13] hippocampal detection of dystrophic neurons (Fig. 6m) , accumulation of undigested vacuoles in the cortex (Fig. 6n ) and possible enlargement of hippocampal lysosomes (Fig. 6o) , suggesting deficits in proteolytic degradation. Nilotinib reversed these effects in the hippocampus (Fig. 6p, r) , where no such structures or defects were detected, and contributed to cortical clearance of vacuoles (Fig. 6q) . In contrast, nilotinib failed to eliminate dystrophic neurons in the hippocampus of parkin −/− mice (Fig. 6s, v) , and was unable to clear vacuoles and accumulating debris in cortex and hippocampus ( Fig. 6t-x) .
Discussion
These studies show that nilotinib increases parkin levels and ubiquitination, leading to parkin-beclin-1 interaction [23] , and amelioration of amyloid pathology. We previously showed that parkin accumulates with intraneuronal Aβ in postmortem AD [13] brains, suggesting that aging may alter parkin stability. Our results are in agreement with previous data showing decreased parkin solubility in Tg-APP mice [22] , while nilotinib increases parkin ubiquitination. WT and not mutant loss-of-function parkin increases proteasome activity [25, 30, 31] , leading to degradation of ubiquitinated proteins, while amyloid stress alters parkin solubility [13] . Previous reports suggested that parkin insolubility is associated with alteration of its activity via increased phosphorylation by Abl [12, 32] . Although our results support the hypothesis that Abl activation leads to decreased parkin activity, we were unable to demonstrate that parkin is an Abl substrate. However, our data suggest that amyloid stress triggers autophagosome formation (LC3-II levels) in AD models, and nilotinib-mediated endogenous parkin ubiquitination can lead to efficient proteasomal recycling and stability, and subsequent interaction with Beclin-1 to mediate autophagosome clearance [22] . Parkin activation via self-ubiquitination is consistent with parkin structure, which contains 9 potential ubiquitination sites on Lys residues [33] , and its function as a hybrid really interesting new gene (RING) and homologous to the E6AP carboxyl terminus (HECT) enzyme [33] [34] [35] [36] [37] [38] , suggesting that ubiquitination may lead to parkin activation. Under normal physiological conditions, parkin is inactive [33, [39] [40] [41] , but cellular stress, including amyloid and autophagosome accumulation may lead to its activation. We previously demonstrated that parkin is autoubiquitinated via both Lys 48 -and Lys 63 -linked ubiquitin chain, leading to ubiquitination of its substrate [26] . Exogenous parkin mediates autophagic clearance in Aβ-expressing animals [13] . Nilotinib-induced Aβ elimination was more efficient than p-Tau clearance, suggesting that p-Tau may affect autophagosome fusion with the lysosomes. The decrease in p-Tau levels in nilotinib-treated mice suggests clearance of free or unbound p-Tau, while the microtubule associated protein Tau remains intact. This is a novel mechanism involving nilotinib-enhanced amyloid degradation to halt progression of AD-like pathology. Since nilotinib is FDA approved, it could be used to test the validity of disease CSF and plasma biomarkers such as p-Tau and β-amyloid.
Although no parkin mutations are associated with AD, manipulation of parkin activity may serve as a disease modifying therapy that would provide an alternative approach to prevent progression from MCI to AD. Gene-wide association studies (GWAS) do not associate Tau with AD, despite the fact that Tau pathology associate correlates with disease progression. Thus, loss of parkin stability, which results in lack of misfolded protein clearance, may have similar effects to Tau modification, which is associated with disease progression, independent of disease-causing mutations or genetic association with AD. Loss of parkin decreases amyloid toxicity in AD models [42, 43] , while parkin deletion leads to more secretion and build-up of extracellular plaques, further underscoring the importance of intracellular Aβ in AD pathology. Parkinmediated K63-linked poly-ubiquitination leads to autophagic clearance [44] . Decreased parkin solubility in association with autophagic or proteasomal defects suggest that aggregated proteins may overwhelm cellular quality control systems, leading to inclusion formation. Therefore, boosting parkin activation may increase autophagy and subsequent protein clearance via parkin-beclin-1 interaction [22] . Although no dementia is reported with parkin mutations in early onset juvenile PD, loss of parkin function does not lead to cytosolic Lewy body inclusions [45] , suggesting that functional parkin mediates cytosolic sequestration of misfolded proteins. In AD, beclin-1 levels are altered [22, 46] , suggesting inefficient execution of beclin-1-dependent autophagy, leading to Aβ and p-Tau accumulation.
These studies provide novel insights into nilotinib effects on parkin ubiquitination and activity, leading to amyloid clearance, and show the effects of an FDA-approved drug as a potential therapy for AD. Ubiquitination may lead to efficient recycling of parkin via the proteasome, leading to decreased parkin insolubility in human aging and AD models. Loss of parkin stability may also result in inefficiency of autophagic clearance due to decreased interaction with Beclin-1. These studies have significant translational and mechanistic impact on the AD field.
